David Gandara

1.3k total citations
17 papers, 790 citations indexed

About

David Gandara is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, David Gandara has authored 17 papers receiving a total of 790 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in David Gandara's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). David Gandara is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). David Gandara collaborates with scholars based in United States, Germany and Finland. David Gandara's co-authors include Michael Kraut, Robert B. Livingston, Frances A. Shepherd, John Crowley, Timothy Winton, Mark B. Hazuka, David H. Johnson, Valerie W. Rusch, Dorothy J. Giroux and Claude Deschamps and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Thoracic and Cardiovascular Surgery.

In The Last Decade

David Gandara

15 papers receiving 769 citations

Peers

Countries citing papers authored by David Gandara

Since Specialization

Citations

This map shows the geographic impact of David Gandara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Gandara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Gandara more than expected).

Fields of papers citing papers by David Gandara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Gandara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Gandara. The network helps show where David Gandara may publish in the future.

Co-authorship network of co-authors of David Gandara

This figure shows the co-authorship network connecting the top 25 collaborators of David Gandara. A scholar is included among the top collaborators of David Gandara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Gandara. David Gandara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	29 Lung-MAP composite signature for immune checkpoint inhibitor (ICI) efficacy in advanced squamous cell lung cancer (SCC) 2022 ·Regular and Young Investigator Award Abstracts ·David Gandara, Xing Hua, Khaled Tolba, David Fabrizio, Lee A. Albacker, Ryan Brennick, Meagan Montesion, (unknown), Stacey J. Adam, Fred R. Hirsch, Karen Kelly, Roy S. Herbst, Michael LeBlanc, Mary W. Redman, Michael C. Wu, David Kozono	0
2	Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies 2019 ·Clinical Lung Cancer ·Christian Schulz, David Gandara, Carmen Galani Berardo, Rachel Rosenthal, Jason Foo, (unknown), Marcus Ballinger, Claire Watkins, Paula Chu	10
3	Clinicopathologic Features of Advanced Squamous NSCLC 2016 ·Journal of Thoracic Oncology ·Mark A. Socinski, Coleman K. Obasaju, David Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz‐Ares, M. Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Thomas E. Stinchcombe, Heather A. Wakelee, Carlos Mayo, Nick Thatcher	111
4	Comparison of Platinum-Based Chemotherapy in Patients Older and Younger than 70 Years: An Analysis of Southwest Oncology Group Trials 9308 and 9509 2010 ·Journal of Thoracic Oncology ·Elizabeth Blanchard, James Moon, Paul J. Hesketh, Karen Kelly, Antoinette J. Wozniak, John Crowley, David Gandara	36
5	Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study 2010 ·Investigational New Drugs ·Robert J. Morgan, Lucille Leong, Warren Chow, David Gandara, Paul Frankel, Agustin A. García, Heinz‐Josef Lenz, James H. Doroshow	38
6	A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium Study. 2008 ·Blood ·Mark Kirschbaum, Leslie Popplewell, Auayporn Nademanee, Vinod Pullarkat, Maria Delioukina, Jasmine Zain, (unknown), (unknown), Paul Frankel, Igor Espinoza‐Delgado, Stephen J. Forman, David Gandara, (unknown)	7
7	Induction Chemoradiation and Surgical Resection for Superior Sulcus Non–Small-Cell Lung Carcinomas: Long-Term Results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160) 2007 ·Journal of Clinical Oncology ·Valerie W. Rusch, Dorothy J. Giroux, Michael Kraut, John Crowley, Mark B. Hazuka, Timothy Winton, David H. Johnson, Lawrence N. Shulman, Frances A. Shepherd, Claude Deschamps, Robert B. Livingston, David Gandara	268
8	Phase II study of oxaliplatin in patients with unresectable, metastatic or recurrent hepatocellular cancer 2005 ·Journal of Clinical Oncology ·Stephen Shibata, Yun Yen, J. H. Doroshow, (unknown), Lawrence D. Wagman, (unknown), K. Clarke, Paul Frankel, Heinz‐Josef Lenz, David Gandara	4
9	Phase II study of oxaliplatin in patients with unresectable, metastatic or recurrent hepatocellular cancer 2004 ·Journal of Clinical Oncology ·Yun Yen, J. H. Doroshow, (unknown), Debora Lim, Lawrence D. Wagman, (unknown), Paul Frankel, (unknown), David Gandara, Stephen Shibata	1
10	Accrual patterns of the Southwest Oncology Group (SWOG) by sex, race/ethnicity, and age: Updated and expanded analyses 2004 ·Journal of Clinical Oncology ·Joseph M. Unger, John J. Crowley, Charles A. Coltman, Laura F. Hutchins, Silvana Martino, J. S. Macdonald, David Gandara, Emily Crawford, Robert B. Livingston, Kathy S. Albain	0
11	SWOG 0019: A phase II study of gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer (SCLC) 2004 ·Journal of Clinical Oncology ·Wallace Akerley, J. McCoy, Paul J. Hesketh, John Crowley, (unknown), David Gandara	2
12	Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: A California Cancer Consortium study 2004 ·Journal of Clinical Oncology ·Syma Iqbal, (unknown), Dongyun Yang, Primo N. Lara, Paul H. Gumerlock, Seiji B. Shibata, Timothy W. Synold, J. H. Doroshow, David Gandara, (unknown)	4
13	Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real‐time reverse transcription‐PCR vs. Relative quantification reverse transcription‐PCR utilizing DNA sequencer analysis of PCR products 2003 ·Journal of Clinical Laboratory Analysis ·Ágnes Juhász, Paul Frankel, Catherine Y. Cheng, H Rivera, (unknown), (unknown), Kim Margolin, Yun Yen, Edward M. Newman, Timothy W. Synold, Sharon P. Wilczynski, Heinz‐Josef Lenz, David Gandara, Kathy S. Albain, Jeff Longmate, James H. Doroshow	12
14	Adjuvant and neoadjuvant treatments for NSCLC 2002 ·Lung Cancer ·Everett E. Vokes, Hak Choy, David Gandara, K. Mattson	16
15	Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial 2002 ·Cancer Chemotherapy and Pharmacology ·Yun Yen, Warren Chow, Lucille Leong, Kim Margolin, Robert J. Morgan, James Raschko, Stephen Shibata, George Somlo, Przemyslaw Twardowski, Paul Frankel, Jeff Longmate, Timothy W. Synold, Edward M. Newman, Heinz-Josef Lenz, David Gandara, James H. Doroshow	7
16	Induction chemoradiation and surgical resection for non–small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160) 2001 ·Journal of Thoracic and Cardiovascular Surgery ·Valerie W. Rusch, Dorothy J. Giroux, Michael Kraut, John Crowley, Mark B. Hazuka, David H. Johnson, Melvyn Goldberg, Frank C. Detterbeck, Frances A. Shepherd, Ronald L. Burkes, Timothy Winton, Claude Deschamps, Robert B. Livingston, David Gandara	187
17	Randomized Study of CODE Versus Alternating CAV/EP for Extensive-Stage Small-Cell Lung Cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group 1999 ·Journal of Clinical Oncology ·Nevin Murray, Robert B. Livingston, Frances A. Shepherd, Keith James, Benny Zee, Adrian Langleben, Michael Kraut, James D. Bearden, J. Wendall Goodwin, C. Grafton, Andrew T. Turrisi, David Walde, (unknown), David Osoba, J. Ottaway, David Gandara	87

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact